Combined use of vitamin D3 and metformin exhibits synergistic chemopreventive effects on colorectal neoplasia in rats and mice

Cancer Prevention Research

Volumn 8, Issue 2, 2015, Pages 139-148

  Li, Wan ^a,b   Wang, Qi Long ^a   Liu, Xia ^a   Dong, Shu Hong ^a   Li, Hong Xia ^a   Li, Chun Yang ^a   Guo, Li Shu ^a   Gao, Jing Miao ^a   Berger, Nathan A ^c   Li, Li ^c   Ma, Lan ^a   Wu, Yong Jie ^a  

^a LANZHOU UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIMETHYLHYDRAZINE; BETA CATENIN; COLECALCIFEROL; CYCLIN D1; DEXTRAN SULFATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MYC PROTEIN; PROTEIN S6; SOMATOMEDIN; VITAMIN D RECEPTOR; ANTINEOPLASTIC AGENT;

ABERRANT CRYPT FOCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLON CANCER; COLON TUMOR; COLORECTAL TUMOR; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; LOW DRUG DOSE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ABERRANT CRYPT FOCI; ANIMAL; COLORECTAL NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; INSTITUTE FOR CANCER RESEARCH MOUSE; WESTERN BLOTTING; WISTAR RAT;

ABERRANT CRYPT FOCI; ANIMALS; ANTICARCINOGENIC AGENTS; BLOTTING, WESTERN; CHOLECALCIFEROL; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; MALE; METFORMIN; MICE; MICE, INBRED ICR; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 84960110899     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0128     Document Type: Article

References (47)

1. o297. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/.
2. Guthrie E, Jackson J, Shaffer J, Thompson D, Tomenson B, Creed F. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease. Am J Gastroenterol 2002;97:1994-9.
3. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in in flammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004;287:G7-17.
4. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18 Suppl 2:1-5.
5. Cho KR, Vogelstein B. Genetic alterations in the adenoma-carcinoma sequence. Cancer 1992;70:1727-31.
6. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987;37:147-51.
7. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998;339:1277-84.
8. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-77.
9. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-5.
10. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 2008;99:2136-41.
11. Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog 2010;49:662-71.
12. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 2008;1:369-75.
13. Higurashi T, Takahashi H, Endo H, Hosono K, Yamada E, Ohkubo H, et al. Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer 2012;12:118.
14. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, et al. Metformin suppresses colorectal aberrant crypt foci in a short-termclinical trial. Cancer Prev Res 2010;3:1077-83.
15. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-73.
16. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67:10804-12.
17. Bel fiore A, Frasca F. IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:381-406.
18. Mulligan AM, O'Malley FP, Ennis M, Fantus IG, Goodwin PJ. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 2007;106:39-47.
19. Ingraham BA, Bragdon B, Nohe A. Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin 2008;24:139-49.
20. Verstuyf A, Carmeliet G, Bouillon R, Mathieu C. Vitamin D: a pleiotropic hormone. Kidney Int 2010;78:140-5.
21. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980;9:227-31.
22. Garland C, Shekelle RB, Barrett-Connor E, Criqui MH, Rossof AH, Paul O. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet 1985;1:307-9.
23. Berkovich L, Sintov AC, Ben-Shabat S. Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies. Invest New Drugs 2013;31:247-55.
24. Grau MV, Baron JA, Sandler RS, Haile RW, Beach ML, Church TR, et al. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 2003;95:1765-71.
25. Hartman TJ, Albert PS, Snyder K, Slattery ML, Caan B, Paskett E, et al. The association of calcium and vitamin D with risk of colorectal adenomas. J Nutr 2005;135:252-9.
26. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000;103:311-20.
27. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001;154:369-87.
28. National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals. Available from: http://grants.nih.gov/grants/olaw/.
29. Williams SS, Alosco TR, Mayhew E, Lasic DD,Martin FJ, Bankert RB. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res 1993;53:3964-7.
30. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254-9.
31. Hamilton SR, Aaltonen LA. Pathology and genetics of tumours of the digestive system: IARC press Lyon; 2000. p. 103-142.
32. Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes 2013;121:27-31.
33. McDonagh MS, Selph S, Ozpinar A, Foley C. Systematic review of the benefits and risks ofmetformin in treating obesity in children aged 18 years and younger. JAMA Pediatrics 2014;168:178-84.
34. Miyoshi H, Kato K, Iwama H, Maeda E, Sakamoto T, Fujita K, et al. Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int J Oncol 2013 Dec 30. [Epub ahead of print].
35. Cai X, Hu X, Cai B, Wang Q, Li Y, Tan X, et al. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo. Oncol Rep 2013;30:2449-57.
36. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
37. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23:824-54.
38. Massoner P, Colleselli D, Matscheski A, Pircher H, Geley S, Jansen Durr P, et al. Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion, and motility. Endocr Relat Cancer 2009;16:795-808.
39. Kim HS, Ingermann AR, Tsubaki J, Twigg SM, Walker GE, Oh Y. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res 2004;64:2229-37.
40. Omdahl JL, DeLuca HF. Regulation of vitamin D metabolism and function. Physiol Rev 1973;53:327-72.
41. White JH. Vitamin D metabolism and signaling in the immune system. Rev Endocr Metab Disord 2012;13:21-9.
42. 2+ pathways. Oncogene 1999;18:7860-72.
43. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
44. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001;411:349-54.
45. Yamada Y, Mori H. Multistep carcinogenesis of the colon in Apc(Min/+) mouse. Cancer Sci 2007;98:6-10.
46. Kwong LN, Dove WF. APC and its modifiers in colon cancer. Adv Exp Med Biol 2009;656:85-106.
47. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.